Kanagawa, Japan

Kenji Asai

This inventor holds 3 USPTO granted patents. Top assignee: Meiji Seika Kabushiki Kaisha. Active years: 1997-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Asai. Retrieved from https://idiyas.com/inventor/kenji-asai-358lxemf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 12.6

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 1997-1998

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kenji Asai: Innovator in Platelet Aggregation Inhibition

Introduction

Kenji Asai is a notable inventor based in Kanagawa-ken, Japan. He has made significant contributions to the field of pharmaceutical compounds, particularly those that inhibit platelet aggregation. With a total of three patents to his name, Asai's work has the potential to impact medical treatments significantly.

Latest Patents

Asai's latest patents include a compound with platelet aggregation inhibitor activity. This compound is represented by a general formula and includes pharmaceutically acceptable salts and solvates that effectively inhibit the agglutination of platelets. The specific structure of the compound is detailed in his patent documentation.

Career Highlights

Kenji Asai is associated with Meiji Seika Kabushiki Kaisha, a prominent company in the pharmaceutical industry. His work at this organization has allowed him to focus on innovative solutions for health-related challenges, particularly in the area of blood disorders.

Collaborations

Asai has collaborated with notable colleagues such as Kiyoaki Katano and Shokichi Ohuchi. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Kenji Asai's contributions to the field of platelet aggregation inhibition highlight his innovative spirit and dedication to advancing medical science. His patents and collaborations reflect a commitment to improving health outcomes through research and development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…